Bortezomib: Clinical profile in lymphoproliferative malignancies Journal Article
| Authors: | O'Connor, O. A. |
| Article Title: | Bortezomib: Clinical profile in lymphoproliferative malignancies |
| Abstract: | In addition to its efficacy in the treatment of multiple myeloma, the proteasome inhibitor bortezomib appears to be active against a variety of other haematological malignancies. In a phase II trial, bortezomib, given twice weekly for 2 weeks of a 3 week cycle to patients with relapsed, refractory or untreated indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL), produced durable responses in 2/7 MCL patients and stable disease in five. Six of eight patients with follicular NHL achieved a durable response (1 CR, 5 PR). In another study, bortezomib was administered to patients with relapsed or refractory indolent or aggressive B-cell lymphoma. Durable responses were seen in 7/12 MCL patients, including three CR. This apparent activity in MCL is particularly encouraging, given its poor prognosis. These early trial results demonstrate that further clinical testing of bortezomib and additional exploration of the multiple biologic effects of proteasome inhibition are warranted in lymphoproliferative malignancies. © 2004 Elsevier Ltd. All rights reserved. |
| Keywords: | cancer survival; treatment outcome; clinical trial; disease course; review; drug efficacy; side effect; drug targeting; cancer grading; ubiquitin; disease association; bortezomib; proteasome; proteasome inhibitor; enzyme inhibition; mantle cell lymphoma; multiple myeloma; sensory neuropathy; thrombocytopenia; radiotherapy; relapse; hodgkin disease; lymphocytopenia; b cell lymphoma; gene activation; correlation analysis; population research; disease severity; lymphoproliferative disease; chronic lymphatic leukemia; lymphocytoma; motor neuropathy; vasculitis; indolent lymphoma; prognosis; human; priority journal |
| Journal Title: | EJC Supplements |
| Volume: | 2 |
| Issue: | 6 |
| ISSN: | 1359-6349 |
| Publisher: | Pergamon-Elsevier Science Ltd |
| Date Published: | 2004-06-01 |
| Start Page: | 18 |
| End Page: | 24 |
| Language: | English |
| DOI: | 10.1016/j.ejcsup.2004.04.005 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Eur. J. Cancer Suppl. -- Export Date: 16 June 2014 -- CODEN: ESJUB -- Source: Scopus |
